456 related articles for article (PubMed ID: 27425179)
1. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
[TBL] [Abstract][Full Text] [Related]
3. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
4. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma.
Tandon N; Rajkumar SV; LaPlant B; Pettinger A; Lacy MQ; Dispenzieri A; Buadi FK; Gertz MA; Hayman SR; Leung N; Go RS; Dingli D; Kapoor P; Lin Y; Hwa YL; Fonder AL; Hobbs MA; Zeldenrust SR; Lust JA; Gonsalves WI; Russell SJ; Kumar SK
Blood Cancer J; 2017 Feb; 7(2):e528. PubMed ID: 28211889
[TBL] [Abstract][Full Text] [Related]
6. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
7. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
8. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Palumbo A; Avet-Loiseau H; Oliva S; Lokhorst HM; Goldschmidt H; Rosinol L; Richardson P; Caltagirone S; Lahuerta JJ; Facon T; Bringhen S; Gay F; Attal M; Passera R; Spencer A; Offidani M; Kumar S; Musto P; Lonial S; Petrucci MT; Orlowski RZ; Zamagni E; Morgan G; Dimopoulos MA; Durie BG; Anderson KC; Sonneveld P; San Miguel J; Cavo M; Rajkumar SV; Moreau P
J Clin Oncol; 2015 Sep; 33(26):2863-9. PubMed ID: 26240224
[TBL] [Abstract][Full Text] [Related]
9. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
[TBL] [Abstract][Full Text] [Related]
11. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
[TBL] [Abstract][Full Text] [Related]
12. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
13. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
[TBL] [Abstract][Full Text] [Related]
14. The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma.
Fan H; Yan W; Li L; Xu J; Liu J; Xu Y; Sui W; Deng S; Du C; Yi S; Zou D; Qiu L; An G
Hematology; 2023 Dec; 28(1):2182156. PubMed ID: 36815749
[TBL] [Abstract][Full Text] [Related]
15. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
Maltezas D; Dimopoulos MA; Katodritou I; Repousis P; Pouli A; Terpos E; Panayiotidis P; Delimpasi S; Michalis E; Anargyrou K; Gavriatopoulou M; Stefanoudaki A; Tzenou T; Koulieris E; Sachanas S; Dimou M; Vassilakopoulos TP; Angelopoulou MK; Pangalis GA; Kyrtsonis MC
Hematol Oncol; 2013 Jun; 31(2):96-102. PubMed ID: 22961993
[TBL] [Abstract][Full Text] [Related]
16. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
[TBL] [Abstract][Full Text] [Related]
17. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
19. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
20. High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma.
Gu Y; Yuan YH; Xu J; Shi QL; Qu XY; Guo R; Bai H; Xu JD; Li JY; Chen LJ
Oncotarget; 2017 Jul; 8(29):48350-48361. PubMed ID: 28418851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
